Prediction of response to biological treatment with monoclonal antibodies in severe asthma

J A Kroes*, S W Zielhuis, E N van Roon, A Ten Brinke

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

24 Citaten (Scopus)
194 Downloads (Pure)


In recent years, major developments have occurred in severe asthma management. Different asthma phenotypes and subgroups have been identified and new treatment options have become available. A total of five monoclonal antibodies are currently approved in severe asthma treatment: omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. These drugs have been shown to reduce exacerbations and to have an oral corticosteroid-sparing effect in many severe asthma patients. However, biological treatment is not successful in all patients and should be discontinued in non-responsive patients. Treating the right patient with the right biologic, and therefore biologic response prediction, has become a major point of interest in severe asthma management. A variety of response outcomes is utilized in the different clinical trials, as well as a huge range of potential predicting factors. Also, regarding the timing of the response evaluation, there are considerable differences between studies. This review summarizes the results from studies on predicting responses and responders to biological treatment in severe asthma, taking into account clinical, functional and inflammatory parameters assessed prior to the start of treatment as well as following a few months of therapy. In addition, future perspectives are discussed, highlighting the need for more research to improve patient identification and treatment responses in the field of biological treatment in severe asthma.

Originele taal-2English
Aantal pagina's15
TijdschriftBiochemical Pharmacology
Vroegere onlinedatum16-apr-2020
StatusPublished - sep-2020

Citeer dit